ライフサイエンスコーパス: cyclin-dependent kinase

1 ionally dependent on CDK7, a transcriptional cyclin-dependent kinase.

2 proteins, could potentially be substrates of cyclin-dependent kinases.

3 c transcription may be directly regulated by cyclin-dependent kinases.

4 orylation mediated by signaling pathways and cyclin-dependent kinases.

5 events premature mitotic entry by inhibiting cyclin-dependent kinases.

6 ks2 are adaptor-like proteins that bind many cyclin-dependent kinases.

7 a) polypeptides that bind to a subset of the cyclin-dependent kinases.

8 under physiological conditions, we show how cyclin-dependent kinase 1 (CDK1) activates the APC/C thr

9 effect of ATR ablation is not due to altered cyclin-dependent kinase 1 (CDK1) activity, DNA damage re

10 ntially promote actin cable assembly through cyclin-dependent kinase 1 (Cdk1) activity.

11 ba is phosphorylated in vitro and in vivo by cyclin-dependent kinase 1 (CDK1) at Ser(119) and Ser(175

12 Phosphorylation by Cyclin-dependent kinase 1 (CDK1) at two conserved sites

13 l4 is phosphorylated in vitro and in vivo by cyclin-dependent kinase 1 (CDK1) during antimitotic drug

14 Here, we report that NSun2 regulates cyclin-dependent kinase 1 (CDK1) expression in a cell cy

15 Downregulation of cyclin A2 and cyclin-dependent kinase 1 (CDK1) recapitulated this phen

16 During mitosis, cyclin-dependent kinase 1 (CDK1) substitutes for mTOR an

17 Mitotic activation of Gwl requires both cyclin-dependent kinase 1 (CDK1)-dependent phosphorylati

18 Cyclin-dependent kinase 1 (CDK1)-mediated phosphorylatio

19 osphorylation of hundreds of proteins by the cyclin-dependent kinase 1 (Cdk1):cyclin B (CycB) complex

20 tein kinase kinase, ribosomal S6 kinase, and cyclin-dependent kinase 1/2 in combination with Bcl-XL i

21 This activates cyclin-dependent kinase 1/cyclin B1 (CDK1/CYCB1) to dire

22 d) and ATR (ATM and Rad3-related) and by the cyclin-dependent kinases 1 and 2.

23 ondria, in which it binds to, and activates, cyclin-dependent kinase-1 (Cdk1).

24 Previously, we have found that cyclin-dependent kinase 11 (CDK11) signaling was essenti

25 Cyclin-dependent kinase 12 (CDK12) promotes transcriptio

26 we use single-cell time-lapse microscopy of Cyclin-Dependent Kinase 2 (CDK2) activity followed by en

27 E1 (CcnE1) is the regulatory subunit of the cyclin-dependent kinase 2 (Cdk2) and controls cell cycle

28 hase of cell cycle, elevation of Cylin E and Cyclin-dependent kinase 2 (CDK2) and downregulation of p

29 hibition of NF90 sensitized HCC cells to the cyclin-dependent kinase 2 (CDK2) inhibitor, roscovitine.

30 Cyclin-dependent kinase 2 (CDK2) is a known regulator in

31 eracetylated, levels of p27 are reduced, and cyclin-dependent kinase 2 (CDK2) is activated upon SIRT1

32 ed a specific PTPN12-insert-loop harboring a cyclin-dependent kinase 2 (CDK2) phosphorylation site.

33 Here, we show that the cell cycle regulator, cyclin-dependent kinase 2 (CDK2), couples primary beta-c

34 Expression of the cyclin-dependent kinase 2 (CDK2), itself a downstream ta

35 E, in conjunction with its catalytic partner cyclin-dependent kinase 2 (CDK2), regulates cell cycle p

36 an alpha-helical structure, upon binding to cyclin-dependent kinase 2 (Cdk2)/cyclin A.

37 Cyclin E and its co-activator, phospho-cyclin-dependent kinase 2 (p-CDK2), regulate G1 to S pha

38 ger-term progression through the cell cycle (cyclin-dependent kinase 2 activity).

39 reased p27, reduced cyclin A1 and attenuated cyclin-dependent kinase 2 activity.

40 icity of protein tyrosine phosphatase N12 by cyclin-dependent kinase 2 phosphorylation orchestrating

41 edict progression of DN, downregulated CDK2 (cyclin-dependent kinase 2).

42 Cyclin D1/D3 and cyclin-dependent kinase 2/4 (cdc2/cdc4) were downregulat

43 phosphorylation is driven by the actions of cyclin-dependent kinases 2 and 4/6 at G1/S cell-cycle ch

44 A and protein levels of cyclins (D1, E1) and cyclin-dependent kinases (2, 4, and 6).

45 Reporter gene assays revealed cyclin-dependent kinase 3 (CDK3) as a direct target of m

46 f the mammalian two-hybrid assay showed that cyclin-dependent kinase 3 (CDK3) directly interacted wit

47 siRNA decreased the expression of cyclin D1, cyclin dependent kinase 4 and 6, and increased the expre

48 ed with induction of the INK4 (inhibitors of cyclin dependent kinase 4) locus leading to cell-cycle a

49 Amplification of chromosome 12q13-q15 (Cyclin-dependent kinase 4 (CDK4) amplicon) is frequently

50 Cyclin D and cyclin-dependent kinase 4 (cdk4) are overexpressed in a

51 we aimed to analyze the participation of the cyclin-dependent kinase 4 (CDK4) in adipose tissue biolo

52 to target different immunogenic mutations in cyclin-dependent kinase 4 (CDK4) that naturally occur in

53 n that was mediated by the neo-expression of cyclin-dependent kinase 4 (CDK4).

54 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.

55 esult that may be due to an effect of p16 on cyclin-dependent kinase 4 levels and IL-12 secretion by

56 EGFR-amplified tumours and a combination of cyclin-dependent kinase 4/6 (CDK4/6) and EGFR inhibitors

57 rotoxicity, we show that the G1/S-regulating cyclin-dependent kinase 4/6 (CDK4/6) pathway is activate

58 (PD), an FDA-approved selective inhibitor of cyclin-dependent kinase 4/6 (CDK4/6), prevents radiation

59 ion phenotype was reversed by treatment with cyclin-dependent kinase 4/6 inhibitor, PD0332991/palboci

60 combination of a MEK inhibitor with PI3K or cyclin-dependent kinase 4/6 inhibitors.

61 Cyclin-dependent kinases 4 and 6 (CDK4/6) are fundamenta

62 We identify cyclin-dependent kinases 4 and 6 (CDK4/6) as essential r

63 The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentia

64 Cyclin-dependent kinases 4 and 6 (CDK4/6) drive progress

65 Cyclin-dependent kinases 4 and 6 (CDK4/6) in complex wit

66 Acquired resistance to cyclin-dependent kinases 4 and 6 (CDK4/6) small-molecule

67 nd an untreated lobe (mean, 165.15 and 230.4 cyclin-dependent kinase 47-positive cells per x20 field,

68 The cyclin-dependent kinase 5 (CDK-5) activating protein, p3

69 action content decreases after inhibition of cyclin-dependent kinase 5 (Cdk5) and ERK1/2.

70 Furthermore, Cadm4, cyclin-dependent kinase 5 (Cdk5) and p39 mRNAs were sign

71 ied in soluble form and is phosphorylated by cyclin-dependent kinase 5 (CDK5) as well as by CaMKII.

72 unction is inhibited upon phosphorylation by cyclin-dependent kinase 5 (Cdk5) at Thr345.

73 ent requires tightly regulated activation of Cyclin-dependent kinase 5 (Cdk5) by two distinct cofacto

74 t of MAPKs and proline-directed kinases like cyclin-dependent kinase 5 (Cdk5) in cell-based as well a

75 We recently identified an essential role for cyclin-dependent kinase 5 (Cdk5) in T-cell activation an

76 Here, we show that cyclin-dependent kinase 5 (Cdk5) is an essential regulat

77 Here, we report for the first time that cyclin-dependent kinase 5 (Cdk5) is an essential regulat

78 Here we show that cyclin-dependent kinase 5 (Cdk5) is required for dbcAMP

79 the algorithm, we showed that inhibition of Cyclin-dependent kinase 5 (Cdk5) led to reduced branchin

80 Dysregulation of cyclin-dependent kinase 5 (cdk5) per relative concentrat

81 Cyclin-dependent kinase 5 (CDK5) phosphorylated DRP1 to

82 CNS myelination, including the noncanonical cyclin-dependent kinase 5 (Cdk5) whose functions are reg

83 Here, we show that cyclin-dependent kinase 5 (Cdk5), a serine-threonine kin

84 Cyclin-dependent kinase 5 (Cdk5), which binds to and is

85 p35, is known to induce aberrant activity of cyclin-dependent kinase 5 (Cdk5), which is associated wi

86 factors, p35 and p39, independently activate Cyclin-dependent kinase 5 (Cdk5), which plays diverse ro

87 ed via activity-dependent phosphorylation by cyclin-dependent kinase 5 (Cdk5).

88 ated by RG108-estrogen receptor 1 (ESR1) and cyclin-dependent kinase 5 (CDK5).

89 (n=12-14; P<0.05), and significantly higher cyclin-dependent kinase 5 activity (n=4; P<0.001).

90 r ratios of p25/p35, indicative of increased cyclin-dependent kinase 5 activity as compared with wild

91 tion is enhanced by prior phosphorylation by cyclin-dependent kinase 5 and antagonized by Fyn phospho

92 purmorphamine treatment was shown to reduce cyclin-dependent kinase 5 in patient cells, suggesting a

93 using roscovitine and siRNA directed towards cyclin-dependent kinase 5) ameliorated the cilia phenoty

94 of histone modifications at the murine Cdk5 (cyclin-dependent kinase 5) locus, given growing evidence

95 ss is accompanied by generation of the Cdk5 (cyclin-dependent kinase 5)-activator p25, up-regulation

96 ion of DeltaFosB, prodynorphin, dynorphin A, cyclin-dependent kinase 5, and increased phosphorylation

97 ing with the phosphatase PP2A and the kinase cyclin-dependent kinase 5.

98 tor erythroid 2-related factor 2, notch, and cyclin-dependent kinase 5.

99 lcineurin, and was opposed by the actions of cyclin-dependent kinase 5.

100 highly conserved phosphorylation site and by cyclin-dependent kinase-5 (Cdk5) at a newly described si

101 The cyclin-dependent kinase 6 (CDK6) and CDK4 have redundant

102 STAT activation and downstream activation of cyclin-dependent kinase 6 (Cdk6) and MycNol3(-/-) MPN Th

103 fects may be mediated by targeting of HMGA2, cyclin-dependent kinase 6 (CDK6), and other predicted mi

104 downregulation of its proven targets, namely cyclin-dependent kinase 6 and Mcl1.

105 s is because of the known ability of vCyclin/cyclin-dependent kinase 6 complex to resist p21 and p27

106 particular, to THZ1, a covalent inhibitor of cyclin-dependent kinase 7 (CDK7).

107 we show that the Mediator-associated kinases cyclin-dependent kinase 8 (CDK8) and CDK19 restrain incr

108 It binds to cyclin-dependent kinase 8 (CDK8) and enhances its kinase

109 Here we identify the Skp2-macroH2A1 (mH2A1)-cyclin-dependent kinase 8 (CDK8) axis as a critical path

110 subunit kinase module, which contains either cyclin-dependent kinase 8 (CDK8) or CDK19.

111 results in diminished CTCF binding, lack of cyclin-dependent kinase 8 (CDK8) recruitment, and an att

112 Cyclin-dependent kinase 9 (CDK9) and CDK12 have each bee

113 Mechanistically, BRD4 is required for cyclin-dependent kinase 9 (CDK9) recruitment and phospho

114 and the enhancer regions, and inhibition of cyclin-dependent kinase 9 (CDK9), that regulates these e

115 omain containing 4 (BRD4) with NF-kappaB and cyclin-dependent kinase 9 (CDK9).

116 e inhibitors of the transcription regulating cyclin-dependent kinase 9 on the development and progres

117 horylated at an N-terminal serine cluster by cyclin-dependent kinase-9 (CDK9), which is recruited int

118 disruption of the core cell cycle regulator CYCLIN-DEPENDENT KINASE A;1 (CDKA;1) and that this repre

119 canonical two-step mechanism in which 1) the cyclin-dependent kinase activating kinase Cak1 phosphory

120 P-TEFb comprises the Cdk9 cyclin-dependent kinase and a cyclin T.

121 Cdc25A dephosphorylates cyclin-dependent kinase and regulates the cell cycle, bu

122 s activated by both the CDC7-Dbf4 kinase and cyclin-dependent kinase and via interactions with CDC45

123 reduced upregulation of p21, an inhibitor of cyclin-dependent kinases, and blocked G1 arrest after TB

124 dc55) prevents nucleolar release of the Cdk (Cyclin-dependent kinase)-antagonising phosphatase Cdc14

125 Aberrant splicing of the cyclin-dependent kinase-associated phosphatase, KAP, pro

126 complexes are not phosphorylated properly by cyclin-dependent kinase/CDC7-Dbf4 kinase and exhibit red

127 model linking cell growth and two sequential cyclin dependent kinase (CDK) activities, and experiment

128 Cyclin dependent kinase (CDK) inhibitors have been the t

129 rosine kinase phosphorylates and inactivates cyclin-dependent kinase (Cdk) 1/2 in response to DNA dam

130 Palbociclib is a potent and specific oral cyclin-dependent kinase (CDK) 4/6 inhibitor that has str

131 Cyclin-dependent kinase (Cdk) activation and RNA polymer

132 with Ku70 to promote NHEJ in G1 when overall cyclin-dependent kinase (CDK) activity is low.

133 tosis is ordered by thresholds of increasing cyclin-dependent kinase (Cdk) activity.

134 ocess is controlled during the cell cycle by cyclin-dependent kinase (CDK) and Dbf4-dependent kinase

135 During mitosis, cyclin-dependent kinase (Cdk) and polo-like kinase (Plk)

136 ty is further required to promote loading of cyclin-dependent kinase (CDK) and proliferating cell nuc

137 hanism demonstrated for other substrates, as cyclin-dependent kinase (CDK) binding-defective mutants

138 Cyclin D-CDK4/6 are the first cyclin-dependent kinase (CDK) complexes to be activated

139 T387 lies in a cyclin-dependent kinase (CDK) consensus sequence, and CD

140 REC-1 is phosphorylated by cyclin-dependent kinase (CDK) in vitro, and mutation of

141 resume cycling after nutrient deprivation or cyclin-dependent kinase (CDK) inactivation express HO in

142 Re-establishing cell cycle control through cyclin-dependent kinase (CDK) inhibition has therefore e

143 The cyclin-dependent kinase (CDK) inhibitor 1A, p21/Cip1, is

144 Cyclin-dependent kinase (CDK) inhibitor drugs induce neu

145 is, we investigated the regulation of p21, a cyclin-dependent kinase (CDK) inhibitor encoded by CDKN1

146 Here we report that p57Kip2, a cyclin-dependent kinase (CDK) inhibitor implicated in th

147 The levels of the cyclin-dependent kinase (CDK) inhibitor p21 are low in S

148 CMV pUL27 results in increased levels of the cyclin-dependent kinase (CDK) inhibitor p21(Cip1).

149 p53-responsive downstream proteins, such as cyclin-dependent kinase (CDK) inhibitor p21, which promo

150 The cyclin-dependent kinase (CDK) inhibitor p27(kip1) is a c

151 N1 stabilizes and increases the level of the cyclin-dependent kinase (CDK) inhibitor p27, which inhib

152 and, mTOR inhibition blunts the induction of cyclin-dependent kinase (CDK) inhibitors (CDKIs), includ

153 The Cip/Kip family of cyclin-dependent kinase (Cdk) inhibitors includes p21(Ci

154 tagal) activity, increased expression of the cyclin-dependent kinase (CDK) inhibitors p16INK4A (CDKN2

155 pendent apoptotic cascades, up-regulation of cyclin-dependent kinase (CDK) inhibitors p21 and p27, an

156 Since cyclin-dependent kinase (CDK) inhibitors, CDKN2A and CDK

157 which could be attenuated by treatment with cyclin-dependent kinase (CDK) inhibitors.

158 growth-arrested because of the expression of cyclin-dependent kinase (CDK) inhibitors.

159 atase and tensin homolog/AKT, retinoblastoma/cyclin-dependent kinase (CDK) N2A-p16(INK4A), and TP53/m

160 moting KMN network recruitment to CENP-C and cyclin-dependent kinase (CDK) regulating KMN network rec

161 Furthermore, our analyses identified a cyclin-dependent kinase (CDK) signaling node that, when

162 hesis that dephosphorylation of four perfect cyclin-dependent kinase (Cdk) sites flanking the CHD pro

163 an initiation factor and essential target of Cyclin-Dependent Kinase (CDK), are targets of the checkp

164 e (UPR) in vivo accumulate p27(Cdkn1b), show cyclin-dependent kinase (Cdk)-1 inhibition, retain their

165 1's activation loop is phosphorylated by the cyclin-dependent kinase (CDK)-activating kinase (Cak1),

166 Instead, the T is phosphorylated by the cyclin-dependent kinase (CDK)-activating kinase, Cak1.

167 e we demonstrate that Ngn3 protein undergoes cyclin-dependent kinase (Cdk)-mediated phosphorylation o

168 Cellular cyclin-dependent kinase (CDK)-mediated Rb inactivation t

169 on is activated during cell cycle transit by cyclin-dependent kinase (Cdk)-mediated Rb phosphorylatio

170 110 to counterbalance its phosphorylation by cyclin-dependent kinase (Cdk).

171 Cyclin-dependent kinase (CDK)4 and CDK6 are frequently o

172 omain antagonist (BA) JQ1 attenuates MYC and cyclin-dependent kinase (CDK)4/6, inhibits the nuclear R

173 of Serine 118 (Ser118) by the TFIIH kinase, cyclin-dependent kinase (CDK)7.

174 cells were highly sensitive to inhibitors of cyclin-dependent kinases (CDK), especially THZ1, a coval

175 s a novel potent small molecule inhibitor of cyclin-dependent kinases (CDK)1, CDK2, CDK5, and CDK9.

176 the protein kinase Wee1, which inhibits the cyclin-dependent kinase Cdk1 in yeast through human cell

177 The activity of cyclin-dependent kinase Cdk1 is essential for DSB repair

178 Cyclin A2 activates the cyclin-dependent kinases Cdk1 and Cdk2 and is expressed

179 Cyclin-dependent kinase (Cdk1) activity is required for

180 cokinetics, and modulation of phosphorylated cyclin-dependent kinase (CDK1) in skin biopsies.

181 Cyclin-dependent kinase (Cdk1) orchestrates progression

182 tral carbon metabolism are controlled by the cyclin-dependent kinase (Cdk1), a major cell cycle regul

183 per cell cycle and is tightly controlled by cyclin-dependent kinase (Cdk1).

184 to reduced phosphorylation of its substrate, cyclin-dependent kinase (Cdk1).

185 ivator of transcription (Tat) as well as the cyclin-dependent kinases CDK13 and CDK11 and positive tr

186 nthesized using a bioinformatics strategy as cyclin-dependent kinases CDK2 and CDK9 inhibitors, which

187 the decrease in KAP expression activates the cyclin-dependent kinase, Cdk2, and this directly promote

188 Here, we report that activation of the cyclin-dependent kinases CDK4 and CDK6 are essential and

189 py; inhibitors of mTOR and inhibitors of the cyclin-dependent kinases CDK4 and CDK6 substantially imp

190 ry domains in a process that is sensitive to cyclin-dependent kinase (CDK4) perturbation.

191 cyclins (D1, D2 and D3) and their associated cyclin-dependent kinases (CDK4 and CDK6) are components

192 Contrary to cell cycle-associated cyclin-dependent kinases, CDK5 is best known for its reg

193 hese functions by binding to, and activating cyclin-dependent kinase, CDK7, which regulates transcrip

194 The mediator complex-associated cyclin dependent kinase CDK8 regulates beta-catenin-depe

195 The Mediator complex-associated cyclin-dependent kinase CDK8 has been implicated in huma

196 Phaeodactylum tricornutum, by binding to two cyclin-dependent kinases, CDKA1 and CDKA2.

197 nding factor TRF2 within the promoter of the cyclin-dependent kinase CDKNIA (p21/CIP1/WAF1).

198 l phosphorylation by the "early" cyclins and cyclin-dependent kinases (cdks) (d-cyclins cdk4/6) and t

199 991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical

200 ammals is strictly controlled by a number of cyclin-dependent kinases (CDKs) and CDK inhibitors (CKIs

201 ylation of hundreds of different proteins by cyclin-dependent kinases (CDKs) and other kinases.

202 The antagonism between cyclin-dependent kinases (Cdks) and the ubiquitin ligase

203 Cyclin-dependent kinases (CDKs) and their associated reg

204 govern eukaryotic cell cycle progression are cyclin-dependent kinases (CDKs) and their partners.

205 Cyclins and cyclin-dependent kinases (CDKs) are hyperactivated in nu

206 Increasing evidence suggests that cyclin-dependent kinases (Cdks) are inappropriately acti

207 Cyclin-dependent kinases (Cdks) are principal drivers of

208 Upon DNA damage, cyclin-dependent kinases (CDKs) are typically inhibited

209 Inhibition of cyclin-dependent kinases (CDKs) caused dramatic reductio

210 Cyclin-dependent kinases (CDKs) control cell division in

211 Cyclin-dependent kinases (CDKs) coordinate cell cycle ch

212 Aberrant activation of cyclin-dependent kinases (CDKs) has been shown to contri

213 ant retinoblastoma-related (RBR) proteins by cyclin-dependent kinases (CDKs) is well documented, but

214 Furthermore, we show that cyclin-dependent kinases (CDKs) phosphorylate PAH1 at se

215 Cyclin-dependent kinases (CDKs) play key roles in cell c

216 Transcriptional cyclin-dependent kinases (CDKs) regulate RNA polymerase

217 S-phase cyclin-dependent kinases (CDKs) stimulate replication in

218 Leishmania mexicana has a large family of cyclin-dependent kinases (CDKs) that reflect the complex

219 , toxicity is blocked by compounds targeting cyclin-dependent kinases (CDKs), as well as by dominant-

220 s regulated at discrete transition points by cyclin-dependent kinases (CDKs).

221 Eukaryotic cell division is driven by cyclin-dependent kinases (CDKs).

222 ity, fork asymmetry, and increased levels of cyclin-dependent kinases (CDKs).

223 sis induced two cellular responses involving cyclin-dependent kinases (CDKs).

224 pecific cyclins that act in association with cyclin-dependent kinases (CDKs).

225 ASE PROMOTING COMPLEX SUBUNIT 10 (APC10) and CYCLIN-DEPENDENT KINASE D (CDKD) proteins from the proli

226 cket protein-E2F binding specificity and how cyclin-dependent kinases differentially regulate pocket

227 CDK5 is an atypical cyclin-dependent kinase family member that regulates man

228 gene, dicer, and a probable uncharacterized cyclin dependent kinase in honey bees, we utilized RNAi

229 Here, we report that CRK1, a G1 cyclin-dependent kinase in Trypanosoma brucei, regulates

230 Ten structurally unrelated inhibitors of cyclin-dependent kinases inhibited ZIKV replication.

231 gehog (Shh) pathway agonist purmorphamine or cyclin-dependent kinase inhibition (using roscovitine an

232 unrecognized convergence of Shh agonism and cyclin-dependent kinase inhibition as potential therapeu

233 genes phosphatase and tensin homolog (PTEN), cyclin dependent kinase inhibitor 2A (CDKN2A), LKB1, and

234 These include the cyclin-dependent kinase inhibitor (CDKI) p18INK4c, the m

235 g a model of resistance to a pharmacological cyclin-dependent kinase inhibitor (CDKi), we show that t

236 e, we show that polymersomes can deliver the cyclin-dependent kinase inhibitor (R)-roscovitine into h

237 l-cycle genes, and we identified the mRNA of cyclin-dependent kinase inhibitor 1A (Cdkn1a, p21) as a

238 ad markedly decreased quiescence and reduced cyclin-dependent kinase inhibitor 1b/c (Cdkn1b/1c) expre

239 tions of knockdowns of the tumor suppressors cyclin-dependent kinase inhibitor 2A (Cdkn2a), transform

240 sistent microbial insult (e.g. LPSs) induces cyclin-dependent kinase inhibitor 2A (CDKN2A/p16(INK4a))

241 d III transcription, and thyroxine decreased cyclin-dependent kinase inhibitor 2A (p16(ink4)) express

242 d by another major POAG risk gene, p16INK4a (cyclin-dependent kinase inhibitor 2A, isoform INK4a).

243 factor beta (TGFbeta) signaling in cultured cyclin-dependent kinase inhibitor 2B (CDKN2B)-deficient

244 mediates GC formation through repression of cyclin-dependent kinase inhibitor CDKN1A (p21(Cip1)).

245 repressor, which leads to expression of the cyclin-dependent kinase inhibitor CDKN1A (p21(CIP1/WAF1)

246 G1 arrest in part through regulation of the cyclin-dependent kinase inhibitor cki-1.

247 Using the cyclin-dependent kinase inhibitor dinaciclib, which down

248 the mRNA expression of osteoblast marker and cyclin-dependent kinase inhibitor genes were all reduced

249 Two homologous cyclin-dependent kinase inhibitor genes, SIAMESE (SIM) a

250 from an alternative reading frame of the p16 cyclin-dependent kinase inhibitor INK4a/ARF gene.

251 We have found that the expression of p21, a cyclin-dependent kinase inhibitor involved in cell cycle

252 cyclin functions specifically to bypass the cyclin-dependent kinase inhibitor p18(INK4c), revealing

253 l cycle regulators cyclins D, A2, and B2 and cyclin-dependent kinase inhibitor p20 in brain tissue.

254 rrest accompanied by increased expression of cyclin-dependent kinase inhibitor p21 and decreased expr

255 The cyclin-dependent kinase inhibitor p21 is an important pl

256 rminus deficiency promotes expression of the cyclin-dependent kinase inhibitor p21(Waf1/Cip1) (Cdkn1a

257 ntly increases transcription and activity of cyclin-dependent kinase inhibitor p21(WAF1/CIP1), leadin

258 53 response, accompanied by induction of the cyclin-dependent kinase inhibitor p21/CIP1, which can be

259 ng the receptors EGFR, ERBB3 (HER3), and the cyclin-dependent kinase inhibitor p27 (CDKN1B) was found

260 tating translation of mRNAs encoding for the cyclin-dependent kinase inhibitor p27(Kip1) and antiapop

261 s T-cell proliferation by the destruction of cyclin-dependent kinase inhibitor p27(kip1), and deletio

262 osol, which causes hyper-accumulation of the cyclin-dependent kinase inhibitor p27, leading to mitoti

263 regulation of c-Myc and stabilization of the cyclin-dependent kinase inhibitor p27/KIP1.

264 differentiation by modulating expression of cyclin-dependent kinase inhibitor p27/p57 and E3 ubiquit

265 The cyclin-dependent kinase inhibitor p57 is highly expresse

266 -line endocrine therapy, with or without the cyclin-dependent kinase inhibitor palbociclib.

267 eased expression of PDGFRbeta and p57kip2, a cyclin-dependent kinase inhibitor, in these cells.

268 r senescence by repressing the expression of cyclin-dependent kinase inhibitor, p21(Waf1/Cip1).

269 The p16(INK4a) (p16) is a cyclin-dependent kinase inhibitor, which has been evalua

270 pecificity between a GHV cyclin and a single cyclin-dependent kinase inhibitor.

271 ase 4 and 6, and increased the expression of cyclin dependent kinase inhibitors (CDKIs), p21 and p27.

272 ar access of signaling cargos and sequesters cyclin-dependent kinase inhibitors (CKIs) involved in ET

273 w targets and associated therapeutic agents: cyclin-dependent kinase inhibitors and poly(adenosine di

274 its downstream targets, cJUN, ATF3, and the cyclin-dependent kinase inhibitors CDKN1A and CDKN2B.

275 reveals differential roles of two homologous cyclin-dependent kinase inhibitors in regulating cell-cy

276 liferation is due in part to derepression of cyclin-dependent kinase inhibitors Ink4a/b, while ineffe

277 ost inhibitors p27(Kip1) and p18(INK4c), two cyclin-dependent kinase inhibitors known to be important

278 ignificant increase in the expression of the cyclin-dependent kinase inhibitors p21 and p27, and a de

279 ore rearrangement and release of sequestered cyclin-dependent kinase inhibitors to elicit immunity an

280 ty, and resulting in accumulation of p53 and cyclin-dependent kinase inhibitors, cell cycle arrest, a

281 ggers a host senescence response mediated by cyclin-dependent kinase inhibitors: p21(CIP1/WAF1) (p21)

282 Cyclin-dependent kinase-like 5 (CDKL5) deficiency is a n

283 d learning and memory.SIGNIFICANCE STATEMENT Cyclin-dependent kinase-like 5 (CDKL5) deficiency is a s

284 Mutations in the X-linked CDKL5 (cyclin-dependent kinase-like 5) gene have been associate

285 CDKL5 (cyclin-dependent kinase-like 5) is mutated in many sever

286 le binding, which is negatively regulated by Cyclin-dependent kinase-mediated phosphorylation of segm

287 uggest that combined inhibition of RAF and d-cyclin-dependent kinases might provide an effective appr

288 ally, we investigated how phosphorylation by Cyclin-dependent kinase on distinct residues regulates p

289 se inhibitor genes were all reduced, that of cyclin-dependent kinase, osteocyte marker, and pro-apopt

290 In this study, we show that in yeast, the cyclin-dependent kinase Pho85/CDK5 provides protection a

291 We find that protein kinase C and cyclin-dependent kinase phosphorylate ANG, enabling ANG

292 Dpb11 binds to S-phase cyclin-dependent kinase-phosphorylated Sld2 and Sld3 to

293 he core MuvB complex simultaneously but that cyclin-dependent kinase phosphorylation of p130 weakens

294 Transcriptional cyclin-dependent kinases play important roles in eukaryo

295 Loss of the adaptor protein cyclin-dependent kinase regulatory subunit 1 (Cks1), a c

296 Dbf4-dependent kinase (DDK) and S-phase cyclin-dependent kinase (S-CDK) are two S phase-specific

297 NUCKS1 (nuclear casein kinase and cyclin-dependent kinase substrate 1) is a 27 kD chromoso

298 eport that Magnaporthe oryzae CKS1 encodes a cyclin-dependent kinase subunit, which plays a significa

299 Cdk5 is an atypical cyclin-dependent kinase that is well characterized for i

300 e human cytomegalovirus (HCMV)-encoded viral cyclin-dependent kinase (v-CDK) UL97 phosphorylates the